Abstract. The present authors previously identified a novel candidate tumor suppressor gene, zinc finger protein 750 (ZNF750), in esophageal squamous cell carcinoma (ESCC) (1). The present study aimed to clarify the clinical significance of ZNF750 expression in ESCC. The association between ZNF750 DNA mutation status and the mRNA expression was examined by whole exome sequence analysis and quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Introduction
Esophageal squamous cell carcinoma (ESCC) is the most common histological type of esophageal cancer worldwide (2) . ESCC tends to have a poor prognosis due to high rates of lymph node metastasis and invasion into surrounding organs (2) . ESCC has been identified to harbor frequent somatic mutations in tumor protein 53 (3), Notch homolog 1, tumor protein P53 (3) and phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit α (4) . However, previous cohorts used to investigate the genomic abnormalities of ESCC were too small to encompass the full range of genomic abnormalities (3, 4) . The present authors have recently performed whole-exome sequence (WES) analysis on 144 Japanese patients with ESCC, and identified a previously uncharacterized mutant gene, zinc finger protein 750 (ZNF750) (1) , which is an essential regulator of epithelial proliferation and differentiation (5) (6) (7) .
In general, in order to identify a sporadic tumor suppressor gene, studies should focus on the high frequency aberrant genomic loci in familial cancer syndromes. As such, it was identified that ZNF750 is located at chromosome 17q25, the same location for the gene responsible for hereditary tylosis esophageal cancer, a familial esophageal cancer (8, 9) .
In a previous study by the present authors, mutations in ZNF750 were identified in 16.7% of ESCC tumors and ZNF750 was identified to be the fifth most frequent mutated genes. Additionally, 87.5% of mutations in ZNF750 led to decreased mRNA expression (1) . Similarly, Lin et al (10) and Zhang et al (11) All patients had a histological diagnosis of ESCC and were closely followed at 3-month intervals. The median follow-up period was 3.9 years. All patients were treated in accordance with the Japan Esophageal Society Guidelines for the treatment of esophageal cancer (12) . Written informed consent was obtained from all patients, and the Institutional Review Board of Kyushu University (Fukuoka, Japan) approved the present study. Sample collection was performed as previously described (13) . Data on patient age, sex, histology, tumor depth of invasion, lymph node metastasis, lymphatic invasion, venous invasion and distant metastasis were obtained from the clinical and pathological records. A total of two patients who exhibited distant metastasis were included in the present study. Of these patients, one exhibited distant lymph node metastasis and the other liver metastasis.
ZNF750 mutation. ZNF750 mutation status data were obtained from WES analysis that the authors of the present study previously performed (1) . RNA from 28 patients of the 144 used in the previous study was available for quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis.
Total RNA extraction and RT. Total RNA from tissues was extracted by a modified AGPC method using ISOGEN (Nippon Gene Co., Ltd., Tokyo, Japan), in which the aqueous phase extraction step by chloroform is unrequired (14) . RT was performed using 8 µg of total RNA with Moloney Murine leukemia virus reverse transcriptase according to the manufacturer's protocol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Quantitative (q)PCR. qPCR reactions were performed using a LightCycler 480 probes master kit (Roche Diagnostics, Indianapolis, IN, USA) and repeated three times as previously described (15) . The following primers were used: ZNF750; sense primer, 5'-GAA CAG GTA CTG CTT CCT GAGC-3' and antisense primer, 5'GAG AGC CTC CGT CAT CTGG-3'; small proline rich protein 1A (SPRR1A); sense primer, 5'-TCC ACC CCA GGA ACC ATG C-3' and antisense primer, 5'-CTT GGT CTT CTG CTG GGC TG-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH); sense primer, 5'-TTG GTA TCG TGG AAG GAC TCTA-3' and antisense primer, 5'-TGT CAT ATT TGG CAG GTT-3. The expression levels of ZNF750 and SPRR1A were normalized by GAPDH as an internal control. The expression levels were calculated as the values relative to the expression level of the cDNA using Human Universal Reference Total RNA with the calibration curve method (Clontech Laboratories, Inc., Mountainview, CA, USA) (16) .
Immunohistochemical analysis. Immunohistochemistry of ZNF750 in 5 randomly selected representative ESCC cases was performed on formalin-fixed, paraffin-embedded tissues as previously described (15) . A polyclonal rabbit anti-ZNF750 antibody (cat. no., HPA023012, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; dilution, 1:100) was used as the primary antibody. Tumor histology was independently reviewed by an experienced pathologist.
The Cancer Genome Atlas (TCGA) data analysis. Paired RNA sequencing and survival data of 86 available patients with ESCC were obtained from TCGA (http://cancergenome. nih.gov/). ZNF750 mRNA expression and survival data were extracted from this reference.
Gene set enrichment analysis (GSEA).
The correlations between ZNF750 expression and previously annotated gene expression signatures were analyzed by applying GSEA (17) . ESCC expression profiles from the National Center for Biotechnology Information (NCBI) gene expression omnibus database (NCBI accession no. GSE2533) were acquired, and analyzed using GSEA, as previously described (18) . Gene sets of ZNF750 targets were extracted from C2 curated gene sets in the Broad Institute database (http://www.broadinstitute .org/gsea/msigdb/collections.jsp).
Cancer Cell Line Encyclopedia (CCLE) data analysis.
Normalized mRNA expression data of 22 available ESCC cell lines were obtained from the CCLE dataset (http://www .broadinstitute.org/ccle/home). ZNF750 and SPRR1A mRNA expression data were extracted from this reference.
Statistical analysis. For continuous variables, statistical analyses were performed using Student's t-test for comparisons of ZNF750 mRNA expression according to the DNA mutation status (un-paired t-test) and between corresponding tumor and normal tissues (paired t-test). The degree of linearity was estimated by Pearson's correlation coefficient. The association between ZNF750 mRNA expression and clinicopathological factors was estimated by the χ 2 test with Yates' correction. Overall survival was estimated using the Kaplan-Meier method, and survival curves were compared using log-rank tests. Univariate and multivariate analyses were used to determine patient prognosis and were performed by Cox regression analysis with a backward stepwise model. Based on the levels of ZNF750 mRNA expression in the Kyushu and the TCGA datasets, patients were divided into two groups using the minimum P-value approach, a comprehensive method that determines the optimal risk separation cutoff point in continuous gene expression measurement (19) . The cutoff values for high and low ZNF750 expression groups were 8.34 (ZNF750/GAPDH expression) in the Kyushu dataset and 2.75 (log2 expression) in the TCGA dataset. All tests were analyzed by using the JMP v.11 software (JMP, Cary, NC, USA). Depth of tumor invasion was classified according to the 7th edition of the International Union against Cancer TNM classification system (20) . Histological grade of the tumor was classified according to the 11th edition of the Japanese Classification of Esophageal Cancer (21) .
Results

Downregulation of ZNF750 expression in ESCC.
It was revealed that 16.7% of patients with ESCC exhibited mutations in the ZNF750 gene (4) (Fig. 1A) . The majority of the mutations (87.5%) were nonsense and/or frameshift mutations that caused reduced expression of ZNF750 (Fig. 1A) . As expected, ZNF750 mRNA expression was significantly lower in patients with ZNF750 nonsense and/or frameshift mutations (n=7) compared with those without mutations (n=21) (P<0.05; Fig. 1B) . Consistent with these data, the immunohistochemical analysis revealed that ZNF750 was stained less intensely in the nuclei of ESCC tumor cells compared with those of normal esophageal epithelial cells in 4 of 5 (80.0%) patients (Fig. 1C) . Additionally, RT-qPCR analysis also demonstrated that ZNF750 mRNA expression in tumor tissues was significantly lower compared with paired normal tissues (P<0.00005) (Fig. 1D) . In fact, ZNF750 mRNA expression levels in tumor tissues were lower compared with normal tissues in 78.9% of 76 patients with ESCC.
Clinicopathological significance of ZNF750 mRNA expression in ESCC.
The association between ZNF750 mRNA expression levels in tumor tissues and clinicopathological factors in ESCC is summarized in Table I . The low ZNF750 expression group (n=37) exhibited a higher frequency of tissues showing poorly differentiated histology (P<0.05) compared with the high expression group (n=39). No significant associations between ZNF750 mRNA expression and age, sex, depth of invasion, lymph node metastasis, lymphatic invasion, venous invasion or distant metastasis were observed.
Prognostic significance of ZNF750 mRNA expression in ESCC.
The overall survival rate of patients in the low ZNF750 expression group was significantly lower compared with the high expression group in the Kyushu dataset (P<0.0005; Fig. 2A ) and the TCGA dataset (P<0.05) (Fig. 2B) . In the univariate analysis, higher T factor (T2-4), lymph node metastasis, lymphovascular invasion and low ZNF750 mRNA expression were significantly associated with a lower overall survival rate (Table II) . The multivariate analysis demonstrated that lymphatic invasion (P<0.05) and low ZNF750 mRNA expression (P<0.05) were independent poor prognostic factors in ESCC (Table II) .
Correlation between ZNF750 mRNA expression levels and epithelial differentiation genes in ESCC. In order to validate the clinicopathological analysis of ZNF750 in ESCC, GSEA was applied to patients with ESCC (NCBI accession no. GSE2533). GSEA demonstrated that ZNF750 expression was significantly correlated with epithelial differentiation genes (Fig. 3A) , which suggests that ZNF750 serves a role in epithelial differentiation in the development of ESCC. Among those genes, SPRR1A, an early epithelial differentiation marker (22), was ranked at the upper level of epithelial differentiation gene signature. The analysis confirmed that ZNF750 mRNA expression was positively correlated with SPRR1A mRNA expression using the CCLE dataset (R=0.71; Fig. 3B ) and the Kyushu dataset (R=0.56; Fig. 3C ). NA, not available; NS, not significant.
Discussion
In the present study, the clinicopathological and prognostic significance of ZNF750 expression, a novel candidate tumor suppressor gene previously described by the present authors (4), was assessed. In order to assess the prognostic significance of ZNF750 expression, two independent ESCC datasets were used. In addition, an association between ZNF750 expression and epithelial differentiation in ESCC was identified. The data of the present study suggested that the downregulation of ZNF750 expression due to inactivating mutations (nonsense/frameshift mutations) induced the development or aggressiveness of ESCC, potentially via dysregulation of esophageal epithelial differentiation. Although other factors such as hyper-methylation or regulation by microRNA may also downregulate the expression of ZNF750, to the best of our knowledge, this is the first study to explore the clinical significance of ZNF750 expression in ESCC.
The present clinicopathological study revealed that the tissues from the low ZNF750 expression group exhibited a higher frequency of poorly differentiated histology compared with the high expression group. Previously, it was suggested that ZNF750 function was associated with epithelial differentiation (5) (6) (7) 10, 11) . These data suggested that a low expression of ZNF750 is associated with tumor aggressiveness in ESCC.
Additionally, it was demonstrated that ZNF750 expression was reduced in tumor tissues, and that low expression of ZNF750 was an independent poor prognostic factor in ESCC. In a previous study by the present authors (4) , it was also demonstrated that the majority of the ZNF750 mutations were accompanied by loss of heterozygosity. These data strongly support the hypothesis that ZNF750 is a tumor suppressor gene, as previously identified by WES analysis. In addition, low ZNF750 expression levels in tumor tissues suggest that it is a promising biomarker capable of predicting poor outcomes for patients with ESCC.
It has been reported that ZNF750 controls epithelial homeostasis by repressing proliferation genes and inducing differentiation genes (5-7). Previous studies indicated that mutations in ZNF750 were pathogenic and disrupt epithelial homeostasis, as observed in psoriasis (23) . The present study suggested that ZNF750 expression was significantly correlated with epithelial differentiation genes such as SPRR1A, an early epithelial differentiation marker, in ESCC. The downregulation of ZNF750 expression in ESCC may also disrupt epithelial homeostasis, followed by the development of ESCC, according to Tetreault et al (24) , who demonstrated that the downregulation of Kruppel like factor 4, an important epithelial differentiation gene, induced malignant transformation of esophageal epithelium. However, the function of the ZNF750 gene in ESCC has not been fully elucidated. Additional large clinical studies and biological experiments for ZNF750 in ESCC are required to clarify this.
In conclusion, ZNF750 expression was low in ESCC tumor tissues, and its reduction was associated with poor differentiation. In addition, low ZNF750 expression was an independent poor prognostic factor in ESCC. These data provide evidence that ZNF750 is a novel tumor suppressor gene, and may be a therapeutic target and useful biomarker of poor clinical outcome in patients with ESCC.
